These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1400646)

  • 21. Behavioral activation and the variability of cerebral glucose metabolic measurements.
    Duara R; Gross-Glenn K; Barker WW; Chang JY; Apicella A; Loewenstein D; Boothe T
    J Cereb Blood Flow Metab; 1987 Jun; 7(3):266-71. PubMed ID: 3495545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease: focal cortical changes shown by positron emission tomography.
    Foster NL; Chase TN; Fedio P; Patronas NJ; Brooks RA; Di Chiro G
    Neurology; 1983 Aug; 33(8):961-5. PubMed ID: 6603596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regional cerebral glucose metabolism associated with ataxic gait--an FDG-PET activation study in patients with olivopontocerebellar atrophy].
    Mishina M; Senda M; Ohyama M; Ishii K; Kitamura S; Terashi A
    Rinsho Shinkeigaku; 1995 Nov; 35(11):1199-204. PubMed ID: 8720328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A longitudinal study of CMRGlu in dementia of Alzheimer type].
    Kuwabara Y; Ichiya Y; Ichimiya A; Sasaki M; Akashi Y; Yoshida T; Fukumura T; Masuda K
    Kaku Igaku; 1994 Oct; 31(10):1255-60. PubMed ID: 7807730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study.
    Choo IH; Lee DY; Youn JC; Jhoo JH; Kim KW; Lee DS; Lee JS; Woo JI
    Alzheimer Dis Assoc Disord; 2007; 21(2):77-84. PubMed ID: 17545731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM
    Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type.
    Mielke R; Herholz K; Grond M; Kessler J; Heiss WD
    Neurobiol Aging; 1992; 13(1):93-8. PubMed ID: 1542386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cortical abnormalities in Alzheimer's disease.
    Foster NL; Chase TN; Mansi L; Brooks R; Fedio P; Patronas NJ; Di Chiro G
    Ann Neurol; 1984 Dec; 16(6):649-54. PubMed ID: 6335378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome.
    Cutler NR
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):309-21. PubMed ID: 2948218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features.
    Kumar A; Schapiro MB; Haxby JV; Grady CL; Friedland RP
    J Psychiatr Res; 1990; 24(2):97-109. PubMed ID: 2213642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double FDG/PET study of the effects of scopolamine in older adults.
    Molchan SE; Matochik JA; Zametkin AJ; Szymanski HV; Cantillon M; Cohen RM; Sunderland T
    Neuropsychopharmacology; 1994 May; 10(3):191-8. PubMed ID: 7916916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain metabolism in autism. Resting cerebral glucose utilization rates as measured with positron emission tomography.
    Rumsey JM; Duara R; Grady C; Rapoport JL; Margolin RA; Rapoport SI; Cutler NR
    Arch Gen Psychiatry; 1985 May; 42(5):448-55. PubMed ID: 3872650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study.
    Pietrini P; Furey ML; Alexander GE; Mentis MJ; Dani A; Guazzelli M; Rapoport SI; Schapiro MB
    Am J Psychiatry; 1999 Mar; 156(3):470-3. PubMed ID: 10080567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease.
    McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB
    CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Age differences in intercorrelations between regional cerebral metabolic rates for glucose.
    Horwitz B; Duara R; Rapoport SI
    Ann Neurol; 1986 Jan; 19(1):60-7. PubMed ID: 3484930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparability of FDG PET studies in probable Alzheimer's disease.
    Herholz K; Perani D; Salmon E; Franck G; Fazio F; Heiss WD; Comar D
    J Nucl Med; 1993 Sep; 34(9):1460-6. PubMed ID: 8355064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET.
    Kushner M; Tobin M; Alavi A; Chawluk J; Rosen M; Fazekas F; Alavi J; Reivich M
    J Nucl Med; 1987 Nov; 28(11):1667-70. PubMed ID: 3499490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cerebral glucose metabolism in autistic children. Study and positron emission tomography].
    De Volder AG; Bol A; Michel C; Cogneau M; Goffinet AM
    Acta Neurol Belg; 1988; 88(2):75-90. PubMed ID: 3260437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging local brain function with emission computed tomography.
    Kuhl DE
    Radiology; 1984 Mar; 150(3):625-31. PubMed ID: 6607481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography and familial Alzheimer's disease: a pilot study.
    Guze BH; Hoffman JM; Mazziotta JC; Baxter LR; Phelps ME
    J Am Geriatr Soc; 1992 Feb; 40(2):120-3. PubMed ID: 1740595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.